0.00
—
Close of 28 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Neximmune
Its shares trade under the ticker NEXI. It has been listed since 12 February 2021.
Neximmune Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Gaithersburg, Maryland. The company went IPO on 2021-02-12. NexImmune, Inc. is a clinical-stage biotechnology company. The firm is engaged in developing an approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology. Its product candidates include NEXI-001 in acute myeloid leukemia (AML) and NEXI-002 in multiple myeloma (MM). The firm provides Artificial Immune Modulation (AIM), which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. The Company’s T cell product candidates are designed to combine the attributes of cellular with reduced potential for toxicities. The company is also developing new AIM nanoparticle constructs and modalities for clinical evaluation in oncology and autoimmune disorders.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 12 Feb 2021
- Employees
- 50
- Website
- neximmune.com ↗
Leadership
Pay as last reported
- Mr. Craig JalbertPresident, Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer, Corporate Secretary, Director, since 2024
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Neximmune Inc employs 50 full-time employees in Gaithersburg, Maryland.
- Neximmune Inc's AIM technology platform constructs synthetic dendritic cells for immune response.
- Neximmune Inc's product candidates include NEXI-001 for acute myeloid leukemia and NEXI-002 for multiple myeloma.
Weaknesses
- Neximmune Inc has a small workforce of 50 employees in the biotechnology sector.
- Neximmune Inc's clinical-stage development requires significant capital investment.
- Neximmune Inc's product candidates are still in clinical stages with no approved products.
Opportunities
- Neximmune Inc's AIM technology platform can expand into oncology and autoimmune disorders.
- Neximmune Inc's clinical-stage biotechnology company can attract investment for product development.
- Neximmune Inc's focus on T cell-mediated immune response may lead to new market opportunities.
Threats
- Neximmune Inc faces competition from other biotechnology companies in the clinical-stage development.
- Neximmune Inc's reliance on clinical trials for product approval poses regulatory risks.
- Neximmune Inc's small workforce may limit its ability to scale operations rapidly.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.